Study of the Efficacy and Safety of Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Community acquired pneumonia (CAP) is one of the most common and morbid conditions encountered in clinical practice, which causes serious morbidity worldwide. In CAP, oxidative stress is linked to inflammation, demonstrated by increased production of interleukin (IL)-6 and tumor necrosis factor (TNF)-α, which attract inflammatory cells and increase oxidant production by these cells. Attenuation of oxidative stress via antioxidants would be expected to result in reduced pulmonary damage. Antioxidants have been found to be effective in alleviating lung injury and protecting against damage of other organs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Age ≥ 18 year

• Clinical: Having symptoms suggestive of CAP such as cough (with or without sputum), fever (\> 38.5°C), pleuritic chest pain or dyspnea.

• Radiologic: consolidations on computed Tomography (CT).

Locations
Other Locations
Egypt
Elmatarya Teaching Hospital
RECRUITING
Cairo
Contact Information
Primary
fatma makram
fatma.aboelhassan@fue.edu.eg
01015000329
Backup
eman elmokadam
Eman.abdellatif@fue.edu.eg
Time Frame
Start Date: 2024-04-01
Estimated Completion Date: 2024-08-01
Participants
Target number of participants: 80
Treatments
Active_comparator: intervention
Placebo_comparator: placebo
Related Therapeutic Areas
Sponsors
Leads: Future University in Egypt

This content was sourced from clinicaltrials.gov